ITeos Therapeutics Inc (NAS:ITOS)
$ 8.34 -0.21 (-2.46%) Market Cap: 304.69 Mil Enterprise Value: -170.82 Mil PE Ratio: 0 PB Ratio: 0.48 GF Score: 46/100

Iteos Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 27, 2023 / 12:35PM GMT
Release Date Price: $11.51 (+1.32%)
Li Watsek
Cantor Fitzgerald LP - Analyst

All right, good morning. And welcome to our fireside chat with iTeos. I'm Li Watsek, biotech analyst at Cantor. And I'm very pleased to be joined today by management team, Michel and Matt here.

Questions & Answers

Li Watsek
Cantor Fitzgerald LP - Analyst

Thank you both for being here. And maybe to kick off, Michel, just give us a brief intro of iTeos. And then maybe talk about where you are with your TIGIT, adenosine programs and what's coming up?

Michel Detheux
iTeos Therapeutics, Inc. - President & CEO

Yes, thank you for the invitation. iTeos today has leveraged 10 years of expertise in tumor immunology to select important targets for immunosuppression in cancer and develop differentiated assets. Today, we have three programs in clinics: TIGIT antibody, partnered with GSK, and two molecules targeting the adenosine pathway where we believe that we have a unique approach that will allow us to tackle the adenosine-mediating suppression.

We have today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot